Other activating mutations, such as KIT V560G in the juxtamembrane domain and KIT D419del in the extracellular domain, are less common but found in patients with aggressive systemic mastocytosis (ASM), mast cell leukemia (MCL), and mast cell sarcoma [47,48,49]. Here, KIT is linked to systemic mastocytosis.